Search clinical trials for: insulin degludec/insulin aspart

Total 2813 results

Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3) (ONWARDS 3)

Diabetes Mellitus, Type 2

United States, Mexico, Puerto Rico, Canada, Denmark, France, Austria, Taiwan, Czechia, Brazil, China, Argentina
Sanofi

Completed

Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM) (B to B)

Diabetes Mellitus, Type 2

Korea, Republic of
Emory University
Novo Nordisk A/S

Completed

IDegLira HIGH Trial

Diabetes Mellitus

United States
University of Texas Southwestern Medical Center

Completed

The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study (SIMPLE)

Diabetes Mellitus, Type 2 | Diabetes

United States
Medical University of Graz

Completed

A Trial to Investigate Efficacy and Usability of Published Best Practice to Control Glycaemia

Diabetes Mellitus, Type 2

Austria
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Aspart vs. Human Insulin During Pregnancy by Women With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United Kingdom, Denmark, Canada, France, Netherlands, Austria, Israel, Finland, Russian Federation, Croatia, Bulgaria, Poland, Ireland, Spain, Norway, Greece, Argentina, Germany
Emory University
Novo Nordisk A/S

Completed

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Sunshine Lake Pharma Co., Ltd.

Completed

A Clinical Study Comparing the Pharmacokinetics and Pharmacodynamic Characteristics of Insulin Degludec Injection (RD15003) and Insulin Degludec Injection (Tresiba®) in Healthy Subjects

Type 2 Diabetes

China
Novo Nordisk A/S

Completed

Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany, South Africa, Russian Federation, Former Serbia and Montenegro, North Macedonia
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes (ADAPT)

Diabetes | Diabetes Mellitus, Type 1

France, Belgium, Luxembourg
Novo Nordisk A/S

Completed

Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689

Diabetes | Diabetes Mellitus, Type 1

France, Denmark, Finland, Russian Federation, Macedonia, The Former Yugoslav Republic of, Hungary, Bulgaria, United Kingdom, Turkey, Czech Republic, Poland
Rush University Medical Center
Novo Nordisk A/S

Completed

Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.

Type 2 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of a Fixed or a Flexible Supplementary Insulin Therapy in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen®) in the Evening or at Bedtime

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Self-control Trial to Evaluate the Remission Rate in Newly Diagnosed Type 2 Diabetes Patients After Treatment With Insulin Aspart

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population

Diabetes | Diabetes Mellitus, Type 1

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years of Age With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Poland
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4) (ONWARDS 4)

Diabetes Mellitus, Type 2

United States, Mexico, Netherlands, Russian Federation, India, Belgium, Japan, Romania, Italy
Novo Nordisk A/S

Completed

Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Slovakia
Nastech Pharmaceutical Company, Inc.

Completed

A Study to Evaluate the Effect of Nasal Insulin on Postprandial Glycemic Control in Type 2 Diabetic Patients

Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany, Austria, South Africa
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Sweden, Finland, France, Norway
National Institute of Neurosciences and Hospital...

Completed

Insulin for Hyperglycemia in Stroke Trial

Hyperglycemia | Stroke, Acute

Bangladesh
Indonesia University

Unknown

The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin Log-G to Lantus

Diabetes Mellitus

Indonesia
Diasome Pharmaceuticals

Completed

Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec

Diabetes Mellitus, Type 1

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of Levemir® Used as Basal Insulin

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Slovakia
Novo Nordisk A/S

Completed

Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Delivery Systems

Denmark
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Canada, Puerto Rico
Yale University
Juvenile Diabetes Research Foundation

Completed

Diluted Insulin in Young Children: Bigger Volumes for Smaller Patients

Type1diabetes

United States
Novo Nordisk A/S

Terminated

Safety of Inhaled Human Insulin in Subjects With Diabetes Mellitus and Chronic Obstructive Pulmonary Disease (COPD) (iINHALE 8)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1 | Chronic Obstructive Pulmonary Disease

Slovakia, Argentina, India, Turkey, Romania, Taiwan, Thailand
Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States, United Kingdom, France, Netherlands, Finland, Germany, Sweden
Sanofi

Terminated

Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting (BASAAL PLUS)

Diabetes Mellitus, Type 2

Netherlands
Karolinska Institutet

Terminated

Insulin Infusion Diabetes Ulcer (IINDU)

Hyperglycemia | Diabetes Mellitus | Insulin Resistance | Surgery | Infection | Ulcers

Sweden
Novo Nordisk A/S

Completed

Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

France, Denmark, Finland, Russian Federation, Macedonia, The Former Yugoslav Republic of, Hungary, Bulgaria, United Kingdom, Turkey, Poland, Czech Republic
Mannkind Corporation
Jaeb Center for Health Research

Active, not recruiting

Afrezza® INHALE-1 Study in Pediatrics (INHALE-1)

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United States
Novo Nordisk A/S

Completed

Human Insulin NPH and Insulin Aspart in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Argentina
Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes

Diabetes | Gestational Diabetes

United States
Novo Nordisk A/S

Completed

Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Insulin in Elderly People With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Croatia, Italy, Slovakia, Denmark, Macedonia, The Former Yugoslav Republic of, Norway, Russian Federation, Finland, France, Poland, Greece, Romania, Sweden, Czech Republic, Argentina
Novo Nordisk A/S

Terminated

Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United Kingdom
Sanofi

Completed

Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus (PUMP)

Diabetes Mellitus, Type 1

France, Australia, Spain, Sweden, United States, Austria, Hungary, Israel, Italy, United Kingdom, Korea, Republic of, Netherlands
Nanjing First Hospital, Nanjing Medical University

Completed

Comparison of Efficacy and Safety of Prandilin and NovoRapid in Newly Diagnosed Type 2 Diabetes

Diabetes Mellitus, Type 2

China
Medical University of Warsaw

Not yet recruiting

Does the Use of Fiasp vs. Asp Lead to the Prolonged TIR in Children With Type 1 Diabetes?

Diabetes Mellitus, Type 1 | Diabetes type1
Novo Nordisk A/S

Completed

Examining the Long-term Safety of Insulin Aspart When Used as a Part of the Treatment for Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Russian Federation, Israel, Croatia, Czech Republic, Slovenia
Novo Nordisk A/S

Completed

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

Diabetes Mellitus, Type 2

India, United States, Thailand, Japan, Germany, Turkey, Hungary, Malaysia, Poland, South Africa, Czechia, Italy, France, Slovenia
Rush University Medical Center
Novo Nordisk A/S

Completed

Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA (DKA)

Diabetic Ketoacidosis

United States
Novo Nordisk A/S

Completed

Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Detemir in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Netherlands
Yale University

Completed

Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin

Type 1 Diabetes Mellitus

United States
Novo Nordisk A/S

Terminated

Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States, Canada

Search clinical trials for: insulin degludec/insulin aspart

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations